Evidence map›Paper›PMID 28461316›Full record

ArticleAntimicrobial agents and chemotherapy2017

Competitive Fitness of Fluconazole-Resistant Clinical Candida albicans Strains.

Christina Popp, Irene A I Hampe, Tobias Hertlein, Knut Ohlsen, P David Rogers, Joachim Morschhäuser

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Virulence Traits and Azole Resistance in KoreanJournal of fungi (Basel, Switzerland) · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Christina PoppInstitute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany.
Irene A I HampeInstitute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany.
Tobias HertleinInstitute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany.
Knut OhlsenInstitute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany.
P David RogersDepartment of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Joachim MorschhäuserInstitute for Molecular Infection Biology, University of Würzburg, Würzburg, Germany joachim.morschhaeuser@uni-wuerzburg.de.
University of Würzburg · DEUniversity of Tennessee Health Science Center · US

Funding

Novel Azole Resistance Mechanisms in Candida albicansR01AI058145 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ROGERS, P. DAVID · 2005 to 2021
$5.8M
Novel Azole Resistance Mechanisms in Candida albicansR21AI058145 · NIAID · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ROGERS, P DAVID · 2004 to 2004
$292k
NIAID NIH HHS R01 AI058145NIAID NIH HHS R21 AI058145
6 · The paper itself

Abstract

The pathogenic yeast

Indexed as

Antifungal AgentsCandida albicansDrug Resistance, FungalErgosterolFluconazoleFungal ProteinsGene Expression Regulation, FungalMutationAntifungal AgentsErgosterolFluconazoleFungal ProteinsCandida albicansdrug resistance evolutionfitness costsgain-of-function mutationtranscription factors

Identifiers

PMID28461316
PMCPMC5487674
OpenAlexW2611712656

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.